Does the media prefer CRDL or HRTX?

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 1 articles in the media. Heron Therapeutics' average media sentiment score of 1.36 beat Cardiol Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SIGA or HRTX?

Heron Therapeutics has a consensus price target of $2.00, indicating a potential upside of 506.06%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Heron Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor SIGA or HRTX?

In the previous week, Siga Technologies and Siga Technologies both had 1 articles in the media. Heron Therapeutics' average media sentiment score of 1.36 beat Siga Technologies' score of 0.37 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NERV or HRTX?

In the previous week, Minerva Neurosciences had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Minerva Neurosciences and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.36 beat Minerva Neurosciences' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer HRTX or SBTX?

Heron Therapeutics presently has a consensus target price of $2.00, suggesting a potential upside of 506.06%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Heron Therapeutics (HRTX) Competitors

$0.33 +0.02 (+5.47%)

As of 09/3/2026 04:00 PM Eastern

Compare

HRTX vs. CRDL, SIGA, NERV, DERM, and SBTX

Should you buy Heron Therapeutics stock or one of its competitors? Heron Therapeutics's main competitors and comparable companies include Cardiol Therapeutics (CRDL), Siga Technologies (SIGA), Minerva Neurosciences (NERV), Journey Medical (DERM), and Silverback Therapeutics (SBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Heron Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Cardiol Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Cardiol Therapeutics' return on equity of -180.44% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 1 articles in the media. Heron Therapeutics' average media sentiment score of 1.36 beat Cardiol Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 362.96%. Heron Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 506.06%. Given Heron Therapeutics' higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Heron Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Heron Therapeutics	$154.90M	0.40	-$20.19M	-$0.19	N/A

Summary

Heron Therapeutics beats Cardiol Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Heron Therapeutics compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Heron Therapeutics has a consensus price target of $2.00, indicating a potential upside of 506.06%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Siga Technologies has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

In the previous week, Siga Technologies and Siga Technologies both had 1 articles in the media. Heron Therapeutics' average media sentiment score of 1.36 beat Siga Technologies' score of 0.37 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Siga Technologies has a net margin of -5.19% compared to Heron Therapeutics' net margin of -22.52%. Siga Technologies' return on equity of -1.55% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

Siga Technologies has higher earnings, but lower revenue than Heron Therapeutics. Siga Technologies is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.45	$23.28M	-$0.05	N/A
Heron Therapeutics	$154.90M	0.40	-$20.19M	-$0.19	N/A

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Heron Therapeutics beats Siga Technologies on 9 of the 15 factors compared between the two stocks.

How does Heron Therapeutics compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Minerva Neurosciences has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Minerva Neurosciences' return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Minerva Neurosciences has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Minerva Neurosciences presently has a consensus target price of $10.33, indicating a potential upside of 120.33%. Heron Therapeutics has a consensus target price of $2.00, indicating a potential upside of 506.06%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Heron Therapeutics has higher revenue and earnings than Minerva Neurosciences. Heron Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Heron Therapeutics	$154.90M	0.40	-$20.19M	-$0.19	N/A

In the previous week, Minerva Neurosciences had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Minerva Neurosciences and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.36 beat Minerva Neurosciences' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Heron Therapeutics beats Minerva Neurosciences on 10 of the 14 factors compared between the two stocks.

How does Heron Therapeutics compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Journey Medical has higher earnings, but lower revenue than Heron Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	3.60	-$11.43M	-$0.22	N/A
Heron Therapeutics	$154.90M	0.40	-$20.19M	-$0.19	N/A

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 14.5% of Journey Medical shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Journey Medical currently has a consensus price target of $14.00, suggesting a potential upside of 77.22%. Heron Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 506.06%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Heron Therapeutics had 1 more articles in the media than Journey Medical. MarketBeat recorded 1 mentions for Heron Therapeutics and 0 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.61 beat Heron Therapeutics' score of 1.36 indicating that Journey Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Journey Medical	Very Positive
Heron Therapeutics	Positive

Journey Medical has a net margin of -8.95% compared to Heron Therapeutics' net margin of -22.52%. Journey Medical's return on equity of -20.23% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-8.95%	-20.23%	-6.60%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

Journey Medical has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

Summary

Journey Medical beats Heron Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Heron Therapeutics compare to Silverback Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, Heron Therapeutics had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for Heron Therapeutics and 0 mentions for Silverback Therapeutics. Heron Therapeutics' average media sentiment score of 1.36 beat Silverback Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Positive
Silverback Therapeutics	Neutral

Silverback Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Silverback Therapeutics' return on equity of -29.62% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Heron Therapeutics presently has a consensus target price of $2.00, suggesting a potential upside of 506.06%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Heron Therapeutics has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.40	-$20.19M	-$0.19	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Heron Therapeutics has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Heron Therapeutics beats Silverback Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Heron Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRTX vs. The Competition

Export

Metric	Heron Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$59.40M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-1.74	787.27	273.29	25.38
Price / Sales	0.40	753.78	613.45	97.56
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	11.00	12.33	12.89	6.14
Net Income	-$20.19M	$2.82B	$3.47B	$349.01M
7 Day Performance	1.04%	2.59%	0.60%	-0.27%
1 Month Performance	-35.48%	6.95%	5.73%	0.68%
1 Year Performance	-75.00%	9.45%	25.35%	14.84%

Heron Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRTX Heron Therapeutics	2.1853 of 5 stars	$0.33 +5.5%	$2.00 +506.1%	-75.2%	$59.40M	$154.90M	N/A	300	Positive News Gap Up
CRDL Cardiol Therapeutics	2.1305 of 5 stars	$1.99 +0.5%	$10.00 +403.8%	+98.2%	$230.04M	N/A	N/A	20
SIGA Siga Technologies	0.1071 of 5 stars	$3.14 -0.2%	N/A	-62.5%	$225.25M	$94.57M	N/A	40
NERV Minerva Neurosciences	1.8744 of 5 stars	$4.61 +1.0%	$10.33 +124.4%	+95.4%	$219.89M	N/A	N/A	9
DERM Journey Medical	1.7793 of 5 stars	$7.57 +2.1%	$14.00 +85.1%	+13.7%	$213.23M	$61.86M	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRTX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heron Therapeutics (HRTX) Competitors

HRTX vs. CRDL, SIGA, NERV, DERM, and SBTX

How does Heron Therapeutics compare to Cardiol Therapeutics?

Summary

How does Heron Therapeutics compare to Siga Technologies?

Summary

How does Heron Therapeutics compare to Minerva Neurosciences?

Summary

How does Heron Therapeutics compare to Journey Medical?

Summary

How does Heron Therapeutics compare to Silverback Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heron Therapeutics (HRTX) Competitors

HRTX vs. CRDL, SIGA, NERV, DERM, and SBTX

How does Heron Therapeutics compare to Cardiol Therapeutics?

Which has more risk & volatility, CRDL or HRTX?

Is CRDL or HRTX more profitable?

Does the media prefer CRDL or HRTX?

Do analysts prefer CRDL or HRTX?

Do institutionals & insiders have more ownership in CRDL or HRTX?

Which has higher valuation and earnings, CRDL or HRTX?

Summary

How does Heron Therapeutics compare to Siga Technologies?

Do analysts recommend SIGA or HRTX?

Which has more risk & volatility, SIGA or HRTX?

Does the media favor SIGA or HRTX?

Is SIGA or HRTX more profitable?

Which has stronger earnings & valuation, SIGA or HRTX?

Do insiders and institutionals believe in SIGA or HRTX?

Summary

How does Heron Therapeutics compare to Minerva Neurosciences?

Is NERV or HRTX more profitable?

Do institutionals & insiders believe in NERV or HRTX?

Which has more risk and volatility, NERV or HRTX?

Do analysts recommend NERV or HRTX?

Which has better valuation & earnings, NERV or HRTX?

Does the media favor NERV or HRTX?

Summary

How does Heron Therapeutics compare to Journey Medical?

Which has preferable earnings & valuation, DERM or HRTX?

Do institutionals & insiders hold more shares of DERM or HRTX?

Do analysts rate DERM or HRTX?

Does the media favor DERM or HRTX?

Is DERM or HRTX more profitable?

Which has more volatility and risk, DERM or HRTX?

Summary

How does Heron Therapeutics compare to Silverback Therapeutics?

Does the media favor HRTX or SBTX?

Is HRTX or SBTX more profitable?

Do analysts prefer HRTX or SBTX?

Which has stronger valuation and earnings, HRTX or SBTX?

Which has more volatility and risk, HRTX or SBTX?

Do institutionals and insiders have more ownership in HRTX or SBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools